GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] can we stop arguing about satiety until somebody posts a number — 56 comments in the full submission. View in context.
713
c/cagrilintide·submitted 1 months ago by u/solene_abubakar

[Discussion] can we stop arguing about satiety until somebody posts a number

Discussionbranch of 8 comments

Question in the title, detail here: can we stop arguing about satiety until somebody posts a number. Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.…

Read the full submission and all 56 comments →

This branch

8 comments, started 1 months ago
u/iman_castellanos108 points·1 months ago

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

replysharereportpermalink
u/nadia_bakker28 points·1 months ago

Do you have the publication or a summary of it?

replysharereportpermalink
u/amylin_amyamylin26 points·1 months ago

REDEFINE is the combination programme

replysharereportpermalink
u/solene_abubakarOP-13 points·1 months ago

Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.

replysharereportpermalink
u/yara_mensah89 points·1 months ago

amylin analogue, different receptor family, different story

replysharereportpermalink
u/karim_restrepo29 points·1 months ago

this is a less-travelled board and the evidence base shows it

replysharereportpermalink
u/zaid_grimaldi22 points·1 months ago

nothing here is approved as a standalone product and research material is not for human use

replysharereportpermalink
u/ravi_sandvik63 points·1 months ago

Are you comparing against a GLP-1 monotherapy result? They are not comparable.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →